[go: up one dir, main page]

TNSN01051A1 - Formes posologiques d'agents de blocage du canal calcium pour le traitement de maladies renales - Google Patents

Formes posologiques d'agents de blocage du canal calcium pour le traitement de maladies renales

Info

Publication number
TNSN01051A1
TNSN01051A1 TNTNSN01051A TNSN01051A TNSN01051A1 TN SN01051 A1 TNSN01051 A1 TN SN01051A1 TN TNSN01051 A TNTNSN01051 A TN TNSN01051A TN SN01051 A TNSN01051 A TN SN01051A TN SN01051 A1 TNSN01051 A1 TN SN01051A1
Authority
TN
Tunisia
Prior art keywords
dosage forms
calcium channel
treatment
kidney disease
channel blockers
Prior art date
Application number
TNTNSN01051A
Other languages
English (en)
Inventor
Paul Foster Adrian
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN01051A1 publication Critical patent/TNSN01051A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’INVENTION DECRIT DES FORMES POSOLOGIQUES UNITAIRES D’AGENTS DE BLOCAGE DU CANAL CALCIUM, TELS QUE L’AMLODIPINE. CES FORMES POSOLOGIQUES COMPRENNENT FACULTATIVEMENT UN AGENT ANTI-HYPERTENSEUR D’UNE CATEGORIE DIFFERENTE. APPLICATION : UTILISATION DE CES FORMES POSOLOGIQUES POUR LE BLOCAGE DU CANAL CALCIUM A DES FINS DE TRAITEMENT D'UNE MALADIE RENALE CHEZ DES ANIMAUX NORMOTENSIFS.
TNTNSN01051A 2000-04-04 2001-04-03 Formes posologiques d'agents de blocage du canal calcium pour le traitement de maladies renales TNSN01051A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008332.9A GB0008332D0 (en) 2000-04-04 2000-04-04 Treament

Publications (1)

Publication Number Publication Date
TNSN01051A1 true TNSN01051A1 (fr) 2005-11-10

Family

ID=9889228

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01051A TNSN01051A1 (fr) 2000-04-04 2001-04-03 Formes posologiques d'agents de blocage du canal calcium pour le traitement de maladies renales

Country Status (12)

Country Link
EP (1) EP1284719A2 (fr)
JP (1) JP2003528927A (fr)
AR (1) AR027763A1 (fr)
AU (1) AU2001239510A1 (fr)
BR (1) BR0109783A (fr)
CA (1) CA2403950A1 (fr)
GB (1) GB0008332D0 (fr)
MX (1) MXPA02009819A (fr)
PA (1) PA8514601A1 (fr)
PE (1) PE20011163A1 (fr)
TN (1) TNSN01051A1 (fr)
WO (1) WO2001074390A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053535A2 (fr) * 2000-12-29 2002-07-11 Bioorganics B.V. Procede de fabrication de l'amlodipine, derives de l'amlodipine et precurseurs associes
AT5874U1 (de) * 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
DK1443917T3 (da) * 2001-11-07 2006-07-17 Synthon Bv Tamsulosintabletter
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
CO5400144A1 (es) * 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
JP4418753B2 (ja) * 2002-09-30 2010-02-24 興和株式会社 腎疾患の予防及び治療用医薬組成物
AU2004208615C1 (en) 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
US20080268049A1 (en) * 2005-02-11 2008-10-30 Dhaliwal Mona Stable Solid Dosage Forms of Amlodipine and Benazepril
NZ561486A (en) 2005-03-15 2011-03-31 Lupin Ltd Pharmaceutical compositions of amlodipine and benazepril
CA2605855A1 (fr) * 2005-04-29 2006-11-09 Hill's Pet Nutrition, Inc. Methodes permettant de prolonger la vie des felins
CA3015964C (fr) * 2016-03-24 2021-08-03 Daiichi Sankyo Company, Limited Medicament pour le traitement d'une maladie renale

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8710493D0 (en) * 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
DE69105040T2 (de) * 1990-05-31 1995-03-23 Pfizer, Inc., New York, N.Y. Arzneimittel gegen Impotenz.
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
JPH07501547A (ja) * 1991-11-26 1995-02-16 セプラコア，インコーポレーテッド 光学的に純粋な（−）アムロジピンを用いる，高血圧，狭心症および他の疾患を治療するための方法および組成物
ATE235251T1 (de) * 1995-03-16 2003-04-15 Pfizer Verwendung von amlodipin, eines seiner salze oder felodipin in kombination mit einem ace-hemmer zur herstellung eines arzneimittels zur behandlung von nicht ischämischer kongestiver herzinsuffizienz
EP0795327A1 (fr) * 1996-03-13 1997-09-17 Pfizer Inc. Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique

Also Published As

Publication number Publication date
WO2001074390A3 (fr) 2002-05-30
AU2001239510A1 (en) 2001-10-15
EP1284719A2 (fr) 2003-02-26
JP2003528927A (ja) 2003-09-30
BR0109783A (pt) 2003-01-21
AR027763A1 (es) 2003-04-09
PE20011163A1 (es) 2001-11-12
CA2403950A1 (fr) 2001-10-11
GB0008332D0 (en) 2000-05-24
WO2001074390A2 (fr) 2001-10-11
PA8514601A1 (es) 2002-08-26
MXPA02009819A (es) 2003-03-27

Similar Documents

Publication Publication Date Title
TNSN01051A1 (fr) Formes posologiques d'agents de blocage du canal calcium pour le traitement de maladies renales
EP1651195A4 (fr) Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
MA25823A1 (fr) Compositions pour le traitement de l'eau.
MA26207A1 (fr) Compositions de traitement de l'eau.
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
EP1641748A4 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
TNSN02015A1 (fr) Composes nouveaux antagonistes de ppar, et compositions les contenant
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
EP1643986A4 (fr) Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
DZ3332A1 (fr) Methode de traitement a l'aide de conjugues ligand-immunogene
EP1583750A4 (fr) Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer
DK1339407T3 (da) Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom
MA27509A1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
DK1257292T3 (da) Anvendelse af IL-18-inhibitorer
DK1764111T3 (da) Vaginalt indgivne anti-dysrytmi midler til behandling af uterin dysrytmi
HN2001000277A (es) PIRROLO [2,1 - a] DIHIDROISOQUINOLINAS
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
TNSN99198A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
EP1483400A4 (fr) Utilisation du recepteur axl pour le diagnostic et le traitement d'une maladie renale
TNSN02038A1 (fr) Composes conjugues de pregabaline et de lactose nouveaux, et compositions les contenant
FR2804984B1 (fr) Systeme d'echafaudage pour capacites de formes diverses
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
EP1172113A4 (fr) Remedes pour le traitement des neuropathies automatiques